Transdermal Drug Delivery System Market – Self-Administration and Home Care Drug Delivery Systems

Overview of This Study:

The study involved four major activities to estimate the current market size for transdermal drug delivery systems. Exhaustive secondary research was done to collect information about the market, peer markets, and the parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across value chain through primary research. Thirdly, both top-down and bottom-up approaches were employed to estimate the complete market size. Finally, the market breakdown and data triangulation was used to estimate the market size of segments and subsegments.

Research Methodologies Followed for This Research:

Primary Research:

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing directors, technology and innovation directors, and related key executives from various key companies and organizations operating in the transdermal drug delivery systems market. The primary sources from the demand side include personnel from research organizations, academic institutes, and purchase managers.

Download PDF Brochure@

Secondary Research:

In the secondary research process, various secondary sources such as the International Association for the Study of Pain (IASP), International Parkinson and Movement Disorder Society, World Parkinson Congress, International Planned Parenthood Federation (IPPF), International Society of Endocrinology, International Diabetes Federation, International Council of Cardiovascular Prevention and Rehabilitation (ICCPR), European Pain Federation (EFIC), European Society of Contraception and Reproductive Health (ESC), European Society of Cardiology, European Parkinson’s Disease Association (EPDA), European Association for the Study of Diabetes (EASD), Asia Pacific Council on Contraception (APCOC), Asian Pacific Society of Cardiology, ASEAN Federation of Endocrine Societies, Guttmacher Institute, National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), United Nations Department of Economic and Social Affairs, directories, industry journals, databases, press releases, and annual reports of the companies have been used to identify and collect information useful for the study of this market.

North America is expected to hold the largest market share during the forecast period

North America is one of the major revenue generating regions in the transdermal drug delivery systems market. The transdermal drug delivery systems market in the region is driven by the rising prevalence of targeted diseases (such as chronic pain, central nervous system disorders, and cardiovascular diseases) in the region, the increasing use of contraceptives, and the increasing number of research activities related to transdermal drug delivery systems.

Key Market Players:

The key players in the transdermal drug delivery systems market are Hisamitsu Pharmaceutical (Japan), Mylan (US), UCB (Belgium), Novartis (Switzerland), and GlaxoSmithKline (UK). Boehringer Ingelheim (Germany), Johnson & Johnson (US), Endo International (Ireland), and Purdue Pharma (US).

Key Questions Addressed by the Report:

 Which are the key players in the market and how intense is the competition?
Emerging countries have immense opportunities for the growth of transdermal drug delivery systems market, will this scenario continue?
Which product market will dominate in future?
What does the future look like for transdermal drug delivery systems?
What are the challenges hindering the adoption of transdermal drug delivery systems?

Request Sample Pages@